About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Sequella Awarded Orphan Drug Status for Its Experimental TB Drug

by Medindia Content Team on October 23, 2007 at 7:45 PM
Font : A-A+

Sequella Awarded Orphan Drug Status for Its Experimental TB Drug

Maryland-based biotechnology company Sequella on Monday announced that FDA and the European Medicines Agency have awarded orphan drug status to its experimental tuberculosis drug SQ109, the Washington Post reports.

Orphan drug status is designed to encourage the development of drugs that are needed but would be prohibitively expensive or unprofitable for drug companies to develop. The designation will give Sequella market-exclusivity rights and a faster, less costly path to approval, according to the Post.

Advertisement

The company hopes that SQ109 will reduce treatment time and the number of drugs required in standard regimens, the Post reports. Orphan drug status is a "big deal" for Sequella, Carol Nacy, the company's CEO, said, adding that it "really makes it a nice working relationship with the FDA, and we always like having good working relations with regulatory agencies".

SQ109 employs a mechanism different to other antibiotics used to treat TB. The experimental drug hinders cell wall synthesis and is active against multiple cellular pathways in a specific group of microorganisms, including TB bacteria.
Advertisement

The drug has shown strong in vitro activity against drug-susceptible and drug-resistant TB, including extensively drug-resistant TB, which is resistant to the two most potent first-line treatments and some of the available second-line drugs. It has also shown strong in vivo activity against pulmonary TB alone and in combination with other drugs.

Source: Kaiser Family Foundation
LIN/C
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Tuberculosis AIDS/HIV Signature Drug Toxicity Silicosis Screening Tests for Tuberculosis 

Recommended Reading
Tuberculosis
Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lung. It may spread to ......
Tuberculosis in Children - Magnitude of the problem
In India nearly 3-4 million children have tuberculosis and another 94 million are at risk for this ....
New and Improved Drug Treatment for Tuberculosis
Bloomberg on Monday examined Bayer's experimental tuberculosis drug moxifloxacin, which could ......
AIDS/HIV
"AIDS is an epidemic disease, a potentially preventable, deadly infection for which there is no cure...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Screening Tests for Tuberculosis
Tuberculin skin test and Interferon – Release Assays are tests used to screen for tuberculosis....
Silicosis
Silicosis is a lung disease caused by inhalation of crystalline free silica dust. It is characterise...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use